Targeting LEDGF/p75 with single-agent inhibitors or in combination with other therapeutic compounds represents a potential avenue for treating MM, according to Ortiz-Hernandez et al. [45]. The gene discussed is PSIP1; the disease is Miyoshi myopathy.